NCT04293562 2026-02-24A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsChildren's Oncology GroupPhase 3 Recruiting1,186 enrolled